Also under exploration for use in SLE are mAb that target B cell surface proteins other than CD20, including anti‐CD19 34 and anti‐CD22 mAb 50, which are aimed at depleting B cells and/or modulating their function. The gene discussed is CD22; the disease is systemic lupus erythematosus.